Opinion|Videos|February 4, 2025
ASH 2024 Highlights: Phase 2 Study of Zanubrutinib Plus Venetoclax in R/R CLL
Panelists discuss how the phase 2 study of zanubrutinib plus venetoclax in relapsed/refractory chronic lymphocytic leukemia (R/R CLL) demonstrated promising efficacy with deep and durable responses, suggesting this combination could be an effective option for previously treated patients while maintaining a manageable safety profile.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- One ASH abstract I wanted to highlight was a phase 2 study of zanubrutinib and venetoclax in the R/R setting. Please share key findings and your impressions.
Advertisement
Related to this article
Watch a highlight reel of breast cancer data from ASCO 2026 that experts anticipate will have the biggest impact on the field.
Teclistamab plus talquetamab met the primary PFS end point and improved overall survival in relapsed/refractory multiple myeloma in MonumenTAL-6.
The FDA has granted priority review to a supplemental application for talazoparib plus enzalutamide in HRR-altered mCSPC.
Camizestrant plus a CDK4/6 inhibitor was approved in the European Union for ER-positive, HER2-negative advanced breast cancer with an emergent ESR1 mutation.
The FDA is reviewing data for daraxonrasib in previously treated pancreatic cancer under the Commissioner’s National Priority Voucher program.
Johannes Schetelig, MD, MSc, discusses phase 3 data for post-transplant cyclophosphamide vs ATLG as GVHD prophylaxis in hematologic malignancies.
Matthew Galsky, MD, discusses the FDA approval of perioperative pembrolizumab plus enfortumab vedotin in MIBC.
The FDA has approved zidesamtinib in patients with locally advanced/metastatic ROS1+ NSCLC who received a prior ROS1 kinase inhibitor.
Advertisement
Advertisement
Trending on OncLive
1
FDA Accepts NDA for Daraxonrasib in Previously Treated Metastatic Pancreatic Cancer
2
Teclistamab Plus Talquetamab Yields Significant Survival Benefits in Earlier-Line R/R Myeloma
3
European Commission Approves Camizestrant Plus CDK4/6 Inhibition for Emergent ESR1-Mutated Advanced Breast Cancer
4
FDA Approves Zidesamtinib in Pretreated ROS1+ NSCLC
5